Dan Gombos

Dan Gombos, MD

Associate Affiliate Member, Research Institute
Houston Methodist


After completing his postdoctoral training in London, UK, Dr. Gombos returned to The University of
Texas M.D. Anderson Cancer Center (MDACC) in Houston, Texas as an Assistant Professor in 2001. He also joined the faculty at The University of Texas Medical Branch in Galveston, Texas in 2005 as a Clinical Assistant Professor of Ophthalmology and Visual Sciences. Dr. Gombos became an Associate Professor at MDACC in 2007, and a Clinical Associate Professor at The University of Texas Medical Branch in 2008. At MDACC, he is currently developing a comprehensive program for the management of patients with intra and periocular tumors. The program will also include special services for children with intraocular retinoblastoma. Dr. Gombos was also a founding physician in the Retinoblastoma Center of Houston, a collaborative effort between The Methodist Hospital, Baylor College of Medicine, Texas Children's Hospital, and MDACC that provides a comprehensive treatment program for retinoblastoma patients and conducts groundbreaking research to improve diagnostic methods and treatment and public awareness campaigns to promote early detection.

Description of Research

Dr. Gombos' research involves clinical trials that use proton beam radiation therapy or gene transfer therapy for pediatric refractory retinoblastoma.

Areas Of Expertise

Retinoblastoma Intraocular tumors Radiation therapy Gene transfer

Consensus Guidelines for Ocular Surveillance of von Hippel-Lindau Disease
Daniels, AB, Chang, EY, Chew, EY, Gombos, DS, Gorin, MB, Shields, CL & Wiley, HE 2024, , Ophthalmology, vol. 131, no. 5, pp. 622-633. https://doi.org/10.1016/j.ophtha.2023.12.014

A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children's Oncology Group study (COG ARET12P1)
Chintagumpala, M, Piao, J, Gombos, D, Chévez-Barrios, P, Brock, L, Dunkel, IJ, Jubran, R, Leahey, AM, Kim, J, OBrien, J, Shields, CL & Rodriguez-Galindo, C 2024, , Pediatric Blood and Cancer, vol. 71, no. 1, e30718, pp. e30718. https://doi.org/10.1002/pbc.30718

Association of choroidal invasion with retinoblastoma survival rates
Loya, A, Ayaz, T, Gombos, DS & Weng, CY 2023, , Journal of AAPOS, vol. 27, no. 1, pp. 32.e1-32.e8. https://doi.org/10.1016/j.jaapos.2022.11.014

Lenticular Anomaly Masking as a Ciliary Body Cyst
Lewis, K, Gombos, DS & Saboo, US 2023, , Ophthalmology, vol. 130, no. 12, pp. 1347. https://doi.org/10.1016/j.ophtha.2023.01.012

The Rise in Immunotherapy and Associated Ocular Toxicities
Mazharuddin, A, Gombos, D & Al-Zubidi, N 2023, . in Global Perspectives in Ocular Oncology. Springer International Publishing, pp. 337-347. https://doi.org/10.1007/978-3-031-08250-4_33

Multicentre analysis of nucleic acid quantification using aqueous humour liquid biopsy in uveal melanoma: implications for clinical testing
Pike, SB, Reid, MW, Peng, CC, Chang, C, Xu, BY, Gombos, DS, Patel, S, Xu, L & Berry, JL 2023, , Canadian Journal of Ophthalmology. https://doi.org/10.1016/j.jcjo.2023.10.024

Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center
Mazharuddin, AA, Whyte, AT, Gombos, DS, Patel, N, Razmandi, A, Chaudhry, AL & Al-Zubidi, NS 2022, , Journal of Immunotherapy and Precision Oncology, vol. 5, no. 4, pp. 98-104. https://doi.org/10.36401/JIPO-22-14

Retinoblastoma in the developed world
Gombos, DS 2022, . in Retinoblastoma: Diagnosis to Management. Nova Science Publishers, Inc. pp. 339-344.

Foreword B
Gombos, DS 2022, . in Retinoblastoma: Diagnosis to Management. Nova Science Publishers, Inc. pp. xi-xi.

Partial spontaneous regression of choroidal melanoma: A case image with histopathology and gene expression profiling
Patel, VR, Gombos, DS, Admirand, J & Ghafoori, SD 2022, , American Journal of Ophthalmology Case Reports, vol. 26, 101517, pp. 101517. https://doi.org/10.1016/j.ajoc.2022.101517

Second Primary Malignancies in Patients With Melanoma Subtypes: Analysis of 120,299 Patients From the SEER Database (2000-2016)
Loya, A, Gombos, DS & Patel, SP 2022, , Frontiers in Oncology, vol. 12, 853076, pp. 853076. https://doi.org/10.3389/fonc.2022.853076

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer
Lin, SH, Lin, HY, Verma, V, Xu-Welliver, M, Thall, PF, Yao, L, Kim, PY, Gombos, DS, Kawedia, JD, Komaki, R, Gomez, DR, Nguyen, QN, OReilly, MS, Lu, C, Fossella, FV, Skoulidis, F, Zhang, J, Tsao, AS, Heymach, JV & Blumenschein, GR 2022, , Cancer Treatment and Research Communications, vol. 30, 100514, pp. 100514. https://doi.org/10.1016/j.ctarc.2022.100514

Ophthalmological Manifestations of Systemic Neoplasia and Its Treatment
Polski, A, Berry, JL & Gombos, DS 2022, . in Albert and Jakobiecs Principles and Practice of Ophthalmology: Fourth Edition. Springer International Publishing, pp. 7865-7890. https://doi.org/10.1007/978-3-030-42634-7_263

Metastatic risk factors associated with class 1A uveal melanoma patients
Ballhausen, A, Urias, E, Gruschkus, SK, Williams, M, Glover, MS, Qin, Y, Gombos, DS & Patel, SP 2021, , Cancers, vol. 13, no. 13, 3292. https://doi.org/10.3390/cancers13133292

Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results from a Single-Arm Phase II Study
Pelster, MS, Gruschkus, SK, Bassett, R, Gombos, DS, Shephard, M, Posada, L, Glover, MS, Simien, R, Diab, A, Hwu, P, Carter, BW & Patel, SP 2021, , Journal of Clinical Oncology, vol. 39, no. 6, pp. 599-607. https://doi.org/10.1200/JCO.20.00605

Response criteria for intraocular retinoblastoma: RB-RECIST
Berry, JL, Munier, FL, Gallie, BL, Polski, A, Shah, S, Shields, CL, Gombos, DS, Ruchalski, K, Stathopoulos, C, Shah, R, Jubran, R, Kim, JW, Mruthyunjaya, P, Marr, BP, Wilson, MW, Brennan, RC, Chantada, GL, Chintagumpala, MM & Murphree, AL 2021, , Pediatric Blood and Cancer, vol. 68, no. 5, e28964. https://doi.org/10.1002/pbc.28964

Reversible HER2 antibody-drug conjugate–induced ocular toxicity
Sharma, A, Riaz, KM, Gill, MS, Patnaik, A, Ulahannan, SV, Wang, JS, Gombos, DS, Ang, Q, Cicic, D, Bergonio, GR, Zhang, C & Wirostko, BM 2022, , Canadian Journal of Ophthalmology, vol. 57, no. 2, pp. 118-126. https://doi.org/10.1016/j.jcjo.2021.02.028

Overview of Ocular Side Effects of Selinexor
Al-Zubidi, N, Gombos, DS, Hong, DS, Subbiah, V, Fu, S, Ahnert, JR, Piha-Paul, SA, Tsimberidou, AM, Karp, DD, Bernstam, FM & Naing, A 2021, , Oncologist, vol. 26, no. 7, pp. 619-623. https://doi.org/10.1002/onco.13756

Targeted cancer therapy and its ophthalmic side effects: A review
Bindiganavile, SH, Bhat, N, Lee, AG, Gombos, DS & Al-Zubidi, N 2021, , Journal of Immunotherapy and Precision Oncology, vol. 4, no. 1, pp. 6-15. https://doi.org/10.36401/JIPO-20-21

Immune-Related Oral, Otologic, and Ocular Adverse Events
Al-Zubidi, N, Page, JC, Gombos, DS, Srivastava, A, Appelbaum, E, Gidley, PW, Chambers, MS & Nader, ME 2021, . in Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology, vol. 1342, Springer, pp. 399-416. https://doi.org/10.1007/978-3-030-79308-1_17